🚀 VC round data is live in beta, check it out!
Sol-Gel Technologies Valuation Multiples
Discover revenue and EBITDA valuation multiples for Sol-Gel Technologies and similar public comparables like OmniAb, Coherus Oncology, Silence Therapeutics, Acepodia and more.
Sol-Gel Technologies Overview
About Sol-Gel Technologies
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
Founded
1997
HQ
Employees
34
Website
Sectors
Financials (LTM)
EV
$229M
Sol-Gel Technologies Financials
Sol-Gel Technologies reported last 12-month revenue of $21M.
In the same LTM period, Sol-Gel Technologies generated had net loss of ($6M).
Revenue (LTM)
Sol-Gel Technologies P&L
In the most recent fiscal year, Sol-Gel Technologies reported revenue of $12M and EBITDA of ($12M).
Sol-Gel Technologies expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $21M | XXX | $12M | XXX | XXX | XXX |
| EBITDA | — | XXX | ($12M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (102%) | XXX | XXX | XXX |
| EBIT Margin | (35%) | XXX | (104%) | XXX | XXX | XXX |
| Net Profit | ($6M) | XXX | ($11M) | XXX | XXX | XXX |
| Net Margin | (28%) | XXX | (92%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Sol-Gel Technologies Stock Performance
Sol-Gel Technologies has current market cap of $249M, and enterprise value of $229M.
Market Cap Evolution
Sol-Gel Technologies' stock price is $89.25.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $229M | $249M | 0.0% | XXX | XXX | XXX | $-3.80 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSol-Gel Technologies Valuation Multiples
Sol-Gel Technologies trades at 11.0x EV/Revenue multiple, and (19.4x) EV/EBITDA.
EV / Revenue (LTM)
Sol-Gel Technologies Financial Valuation Multiples
As of March 21, 2026, Sol-Gel Technologies has market cap of $249M and EV of $229M.
Equity research analysts estimate Sol-Gel Technologies' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sol-Gel Technologies has a P/E ratio of (42.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $249M | XXX | $249M | XXX | XXX | XXX |
| EV (current) | $229M | XXX | $229M | XXX | XXX | XXX |
| EV/Revenue | 11.0x | XXX | 19.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (19.4x) | XXX | XXX | XXX |
| EV/EBIT | (31.3x) | XXX | (19.1x) | XXX | XXX | XXX |
| P/E | (42.1x) | XXX | (23.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (16.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sol-Gel Technologies Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Sol-Gel Technologies Margins & Growth Rates
Sol-Gel Technologies' revenue in the last 12 month declined by (75%).
Sol-Gel Technologies' revenue per employee in the last FY averaged $0.6M.
Sol-Gel Technologies Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (75%) | XXX | 118% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (102%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (59%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 21% | XXX | 50% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 114% | XXX | 154% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 204% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Sol-Gel Technologies Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| OmniAb | XXX | XXX | XXX | XXX | XXX | XXX |
| Coherus Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Silence Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Acepodia | XXX | XXX | XXX | XXX | XXX | XXX |
| Ourofino | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sol-Gel Technologies M&A Activity
Sol-Gel Technologies acquired XXX companies to date.
Last acquisition by Sol-Gel Technologies was on XXXXXXXX, XXXXX. Sol-Gel Technologies acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Sol-Gel Technologies
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSol-Gel Technologies Investment Activity
Sol-Gel Technologies invested in XXX companies to date.
Sol-Gel Technologies made its latest investment on XXXXXXXX, XXXXX. Sol-Gel Technologies invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Sol-Gel Technologies
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sol-Gel Technologies
| When was Sol-Gel Technologies founded? | Sol-Gel Technologies was founded in 1997. |
| Where is Sol-Gel Technologies headquartered? | Sol-Gel Technologies is headquartered in China. |
| How many employees does Sol-Gel Technologies have? | As of today, Sol-Gel Technologies has over 34 employees. |
| Who is the CEO of Sol-Gel Technologies? | Sol-Gel Technologies' CEO is Moshe Arkin. |
| Is Sol-Gel Technologies publicly listed? | Yes, Sol-Gel Technologies is a public company listed on Nasdaq. |
| What is the stock symbol of Sol-Gel Technologies? | Sol-Gel Technologies trades under SLGL ticker. |
| When did Sol-Gel Technologies go public? | Sol-Gel Technologies went public in 2018. |
| Who are competitors of Sol-Gel Technologies? | Sol-Gel Technologies main competitors are OmniAb, Coherus Oncology, Silence Therapeutics, Acepodia. |
| What is the current market cap of Sol-Gel Technologies? | Sol-Gel Technologies' current market cap is $249M. |
| What is the current revenue of Sol-Gel Technologies? | Sol-Gel Technologies' last 12 months revenue is $21M. |
| What is the current revenue growth of Sol-Gel Technologies? | Sol-Gel Technologies revenue growth (NTM/LTM) is (75%). |
| What is the current EV/Revenue multiple of Sol-Gel Technologies? | Current revenue multiple of Sol-Gel Technologies is 11.0x. |
| Is Sol-Gel Technologies profitable? | No, Sol-Gel Technologies is not profitable. |
| What is the current net income of Sol-Gel Technologies? | Sol-Gel Technologies' last 12 months net income is ($6M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.